Dasatinib induces rapid reduction in spleen size in patients with CML. (A) A blood sample was withdrawn before and 1 hour after dasatinib intake and white blood cell (WBC) and lymphocyte numbers were quantified and correlated to dasatinib plasma concentration. (B) Quantification of the spleen volume (Vol), caudal (length), anteroposterior (width), and transverse (thickness) axes (upper row) before and after dasatinib intake. The lower row shows the percentage of change for each parameter. (C) Correlations between the FC of lymphocytes before and after dasatinib intake and the change of spleen volume shown as percentage of reduction, the change of CA shown as percentage of reduction and dasatinib plasma concentration, and between the change of spleen volume and years on dasatinib therapy. n = 26 determinations from 14 patients at different time points; analyzed by paired t test, Wilcoxon paired t test, and/or Pearson correlation coefficient, as appropriate. ∗P < .05; ∗∗P < .01; ∗P < .05; ∗∗∗P < .001; ∗∗∗∗P < .0001.